Stocksigma LogoStocksigma Logo

Sun Pharma Licenses Lerodalcibep Globally Excluding US and China from LIB Therapeutics

Sun Pharma secured exclusive worldwide commercialization and manufacturing rights, excluding the US and China, for LIB Therapeutics' lerodalcibep (Lyrokaul

Sun Pharma Licenses Lerodalcibep Globally Excluding US and China from LIB Therapeutics

Sun Pharmaceutical Industries Ltd 路 Press Release 路 28 Sept 2026, 1:50 pm

Sun Pharma Licenses Lerodalcibep Globally Excluding US and China from LIB Therapeutics Sun Pharma secured exclusive worldwide commercialization and manufacturing rights, excluding the US and China, for LIB Therapeutics' lerodalcibep (Lyrokaul in the EU), an EMA-approved once-monthly PCSK9 inhibitor for hypercholesterolaemia. Under the agreement, LIB receives upfront and milestone payments plus net sales royalties. The deal expands Sun Pharma鈥檚 innovative portfolio into an ex-US/China PCSK9 market valued at US$3.7B as of MAT Q2'26 (Europe accounting for US$2.9B), growing at a 38% CAGR, while the global market approaches US$7B in 2026.

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements